The year brought a consolidation of capital and additional funding for resident companies in the form of subsidies, crowdfunding and two major rounds of fundraising
Romainville, France, May 31, 2016 – Biocitech, the city complex for healthcare and biotechnology companies located at the edge of Paris, today announces its residents’ results for 2015. The survey of the complex’s resident companies reveals an increase of 10.3% in overall revenue, from €62 million ($69.1m) in 2014 to €69.1 million ($77m) in 2015.
For some, the increase was very significant, ranging from 50% for In Situ Environnement (in French), Mitologics, Sibio (in French), and Spectralys, to 131% for biotechnology news publisher Biotech Info 3.0 (in French). 2015 also saw a rise of nearly 80% in subsidies (from Bpifrance-AIMA[1], H2020 SME-Instruments[2], RHU[3], FUI[4], and DGA[5]), with a total of almost €2 million ($2.23m) received. The outlook for 2016 also confirms the appeal of crowdfunding, which provided Biocitech resident PrimaDiag with €165,000 ($184,000). One highlight of 2015 was the listing of Biophytis on Euronext, raising €16 million ($17.83m), with Galapagos admitted to trading on NASDAQ, generating €300 million ($334.4m). This injection of funds allows both companies to pursue their ambitious plans for development.
The entrepreneurial drive of Biocitech’s residents is borne out by business indicators, with partnerships with foreign companies and presentations at trade fairs, conventions and conferences on the rise, Henoïda being awarded 'innovative young business' status and Spectralys gaining formal recognition for its fair management practices. The other indicators reviewed – particularly employee and researcher numbers, preclinical and clinical trials, numbers of clients and contracts signed, the number of partnerships between residents and membership of competitiveness clusters – all remain stable, providing evidence that residents’ business models are robust.
Last year also saw the completion of a number of projects launched in mid-2014 to modernize the complex: complete refurbishment of the Galien building to accommodate the Galapagos business, modernization of the auditorium, renovation of utilities (heat, cold, vacuum energy, compressed air and deionized water systems) and construction of a new building for facilities management. The full modernization project also involves the demolition of obsolete buildings and the remediation of land to be banked for expanding the site.
“The takeover of Biocitech by the CDC (French funding agency Caisse des Dépôts et Consignations) in July 2015 confirms the additional impetus generated by its first capital increase in May 2014,” said Hammou Allali, director of housing, real estate investment and tourism at the CDC’s Investments and Local Development department and Biocitech’s new chairman. “We are committed to ensuring a sustainable program of investment by CDC, to expand the Biocitech complex and foster excellence and innovation in the Seine-Saint-Denis area.”
“I am delighted with this improvement in residents’ revenue,” said Jean-François Boussard, head of sales for Biocitech’s real estate portfolio. “The consolidation of overall business growth for the site’s residents and the arrival of three new companies in 2015 show the appeal of our complex, which continues to enjoy the support of the Medicen Paris Region, Cap Digital and Systematic competitiveness clusters, and a network of external partners such as the Chamber of Commerce and Industry (CCI) and the Paris public hospital system (AP-HP). Resident companies know how to find novel avenues for developing their businesses; we are actively committed to supporting them in setting up on the site and to attracting new diagnostics, medical devices and environmental companies, while also providing them with fertile ground for growth.”
Biocitech’s policy of hosting conferences and seminars of national and international importance will continue throughout 2016. Twenty-three events were held in the new auditorium in 2015, including a number of meetings of the Adebiotech think tank, and, in partnership with the Seine-Saint-Denis Chamber of Commerce and Industry (CCI), the highly successful Biocitech Funding Days, which will be repeated in June 2016.
About BIOCITECH
BIOCITECH is a city complex for healthcare and biotechnology companies. Located at the edge of Paris, BIOCITECH fosters business innovation and growth (plug&grow) and provides a complete range of services to residents from inception through to business maturity (plug&live).
BIOCITECH’s package includes real estate services, scientific services, technical services and communal services that support entrepreneurial development. BIOCITECH is ICPE certified (Equipment Certified to Protect the Environment) and provides entrepreneurs with secure premises of a high technological standard.
BIOCITECH generates strong synergies and numerous collaborations for resident firms that are at the forefront of innovation. BIOCITECH is a key element in the Medicen Paris region’s world-class competitiveness hub for health and new therapies and also belongs to the Cap Digital and Systematic clusters.
For more information: www.biocitech.paris / Twitter / LinkedIn
Romainville, France, May 31, 2016 – Biocitech, the city complex for healthcare and biotechnology companies located at the edge of Paris, today announces its residents’ results for 2015. The survey of the complex’s resident companies reveals an increase of 10.3% in overall revenue, from €62 million ($69.1m) in 2014 to €69.1 million ($77m) in 2015.
For some, the increase was very significant, ranging from 50% for In Situ Environnement (in French), Mitologics, Sibio (in French), and Spectralys, to 131% for biotechnology news publisher Biotech Info 3.0 (in French). 2015 also saw a rise of nearly 80% in subsidies (from Bpifrance-AIMA[1], H2020 SME-Instruments[2], RHU[3], FUI[4], and DGA[5]), with a total of almost €2 million ($2.23m) received. The outlook for 2016 also confirms the appeal of crowdfunding, which provided Biocitech resident PrimaDiag with €165,000 ($184,000). One highlight of 2015 was the listing of Biophytis on Euronext, raising €16 million ($17.83m), with Galapagos admitted to trading on NASDAQ, generating €300 million ($334.4m). This injection of funds allows both companies to pursue their ambitious plans for development.
The entrepreneurial drive of Biocitech’s residents is borne out by business indicators, with partnerships with foreign companies and presentations at trade fairs, conventions and conferences on the rise, Henoïda being awarded 'innovative young business' status and Spectralys gaining formal recognition for its fair management practices. The other indicators reviewed – particularly employee and researcher numbers, preclinical and clinical trials, numbers of clients and contracts signed, the number of partnerships between residents and membership of competitiveness clusters – all remain stable, providing evidence that residents’ business models are robust.
Last year also saw the completion of a number of projects launched in mid-2014 to modernize the complex: complete refurbishment of the Galien building to accommodate the Galapagos business, modernization of the auditorium, renovation of utilities (heat, cold, vacuum energy, compressed air and deionized water systems) and construction of a new building for facilities management. The full modernization project also involves the demolition of obsolete buildings and the remediation of land to be banked for expanding the site.
“The takeover of Biocitech by the CDC (French funding agency Caisse des Dépôts et Consignations) in July 2015 confirms the additional impetus generated by its first capital increase in May 2014,” said Hammou Allali, director of housing, real estate investment and tourism at the CDC’s Investments and Local Development department and Biocitech’s new chairman. “We are committed to ensuring a sustainable program of investment by CDC, to expand the Biocitech complex and foster excellence and innovation in the Seine-Saint-Denis area.”
“I am delighted with this improvement in residents’ revenue,” said Jean-François Boussard, head of sales for Biocitech’s real estate portfolio. “The consolidation of overall business growth for the site’s residents and the arrival of three new companies in 2015 show the appeal of our complex, which continues to enjoy the support of the Medicen Paris Region, Cap Digital and Systematic competitiveness clusters, and a network of external partners such as the Chamber of Commerce and Industry (CCI) and the Paris public hospital system (AP-HP). Resident companies know how to find novel avenues for developing their businesses; we are actively committed to supporting them in setting up on the site and to attracting new diagnostics, medical devices and environmental companies, while also providing them with fertile ground for growth.”
Biocitech’s policy of hosting conferences and seminars of national and international importance will continue throughout 2016. Twenty-three events were held in the new auditorium in 2015, including a number of meetings of the Adebiotech think tank, and, in partnership with the Seine-Saint-Denis Chamber of Commerce and Industry (CCI), the highly successful Biocitech Funding Days, which will be repeated in June 2016.
About BIOCITECH
BIOCITECH is a city complex for healthcare and biotechnology companies. Located at the edge of Paris, BIOCITECH fosters business innovation and growth (plug&grow) and provides a complete range of services to residents from inception through to business maturity (plug&live).
BIOCITECH’s package includes real estate services, scientific services, technical services and communal services that support entrepreneurial development. BIOCITECH is ICPE certified (Equipment Certified to Protect the Environment) and provides entrepreneurs with secure premises of a high technological standard.
BIOCITECH generates strong synergies and numerous collaborations for resident firms that are at the forefront of innovation. BIOCITECH is a key element in the Medicen Paris region’s world-class competitiveness hub for health and new therapies and also belongs to the Cap Digital and Systematic clusters.
For more information: www.biocitech.paris / Twitter / LinkedIn
